Novo Nordisk A/S (BUL:NOV)
Bulgaria · Delayed Price · Currency is BGN · Price in EUR | Market Cap | 275.96B -35.3% |
| Revenue (ttm) | 83.82B +5.6% |
| Net Income | 29.63B +4.8% |
| EPS | 6.67 +5.0% |
| Shares Out | n/a |
| PE Ratio | 9.31 |
| Forward PE | 11.76 |
| Dividend | 3.06 (4.64%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 75 |
| Open | 33.75 |
| Previous Close | n/a |
| Day's Range | 33.70 - 33.75 |
| 52-Week Range | 30.34 - 54.36 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
(RTTNews) - Novo Nordisk A/S (NVO), a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) informed the company that its Biologics License Application (BLA) review of den...
FDA Postpones Review of Novo Nordisk's Hemophilia A Drug, NVO Eyes 2027 U.S. Launch
FDA Postpones Review of Novo Nordisk's Hemophilia A Drug, NVO Eyes 2027 U.S. Launch
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues
The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish drugmaker said on Friday.
Novo provides update on the denecimig Biologics License Application (BLA) in the US
Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, ...
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
Novo has improved its pipeline through licensing deals. The recent agreements it has signed could yield powerful, differentiated weight-loss options.
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk maintains high profitability through its specialization in chronic disease management and metabolic health. Pfizer is aggressively diversifying its portfolio through strategic acquisition...
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs...
Lightning Round: Sprouts is a winner, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Sprouts Farmers Market, Taiwan Semi, Novo Nordisk, NetApp, and Kenvue.
Trump Medicare drug pricing model may apply to only four companies after exemptions
A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting companies that signed separate "most favored nation" pricing agre...
Novo Nordisk's Wegovy Reduces Liver Fat In Obesity Without Diabetes
(RTTNews) - Thursday, Novo Nordisk A/S (NVO) announced a post hoc analysis of data from a STEP UP trial, showing that Wegovy reduced liver fat in adults with obesity without diabetes.
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide al...
Novo Nordisk (NVO) Unveils Promising CagriSema Weight Management Data at EASD 2026
Novo Nordisk (NVO) Unveils Promising CagriSema Weight Management Data at EASD 2026
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche is increasingly looking like a notable contender in this fast-growing area.
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk for...
Novo Nordisk announces new data on CagriSema
The company states: “Novo Nordisk (NVO) announced new data on how CagriSema works inside both the brain and body, presented at the European Association for the Study of Diabetes Annual…
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
Patients who switched from weight-loss injections to Novo Nordisk's daily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish drugmaker s...
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
People who switched from obesity injections to Novo's new Wegovy pill continued to lose weight after three months, according to an analysis of real-world data the company presented. Patients who switc...
Novo Nordisk Gives Uninspiring Outlook
Investors were hopeful for a better growth estimate.
Novo Nordisk (NVO) Reports Cardiovascular Benefits of Higher Semaglutide Dose in Type 2 ...
Novo Nordisk (NVO) Reports Cardiovascular Benefits of Higher Semaglutide Dose in Type 2 Diabetes Patients
Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
Novo vs. Eli Lilly: Study Shows Ozempic Advantage over Mounjaro — Why This Matters for NVO Investors
Danish drug giant Novo ($NVO), in a Tuesday press statement, announced key findings from a real-world study that pitched its diabetes drug against Eli Lilly’s ($LLY). The study compared semaglutide,…
Novo Nordisk enters into license agreement with Hengrui Pharma on HRS-1596
The company stated: “Novo Nordisk (NVO) announced that it has entered into a license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor, (GLP-1R, and gastric ...
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compa...
Novo's Ozempic Shows 6% Lower MACE Risk In Real-World Comparison With Mounjaro
(RTTNews) - Novo Nordisk A/S (NVO) reported that adults with type 2 diabetes who increased their dose of Ozempic (semaglutide) from 1 mg to 2 mg were associated with a statistically significant 6% low...
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Eli Lilly said its oral obesity drug, Foundayo, offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's Ozempic pill in adults with type 2 diabetes, citing dat...